All News

PET CT Imaging to Define Risk of Progression from PSO to PsA Dr. Peter Nash ( @drpnash) discusses Abstract 1018 at #ACR22 Convergence. https://t.co/Wk3ibuh9ip https://t.co/FcLjDMJCgr

https://bit.ly/3VwlogZ

Low-grade Proteinuria in Non Renal Lupus: Should We be Worried? Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22 https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2

https://bit.ly/3P2vsvD

Opioid use in PsA and SpA Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence https://t.co/Doxbk7qW33 https://t.co/2UX07T2JpS

https://bit.ly/3B8rLPw

CAR-T Therapies in Antiphospholipid Antibody Syndrome Dr. Putman and Dr. Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells https://t.co/VeAgl3qz8J https://t.co/rN4ZLM5Ft8

https://bit.ly/3UB6q82

New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe! Rheum Manpower Needs - More Programs https://t.co/xGXVFMkNra https://t.co/hcRGVMFZPE

https://bit.ly/3W8a5vt

Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/PEPmzZPeFr https://t.co/sS7IiYW9PR

https://bit.ly/3ullgVv

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/2QL2mz7Zhk https://t.co/YQ7jG1WnAG

https://bit.ly/3urJHR3

View our interactive case study from the #SLEEducatorsNetwork to discover how you can apply the concept of disease modification to your patients with lupus. #Sponsored by GSK USMA https://t.co/not76wZPnI https://t.co/Reot2JbWpF

https://bit.ly/3Vw5zqE

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/11dneH04bv https://t.co/pp0ELe5mqV

https://bit.ly/3Hb0dfY

NRMP Results for rheumatology 2022 : - Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied) - Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied) WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/sqcIXxWrxx https://t.co/9xeUQeAuDD

https://bit.ly/3H7uvjY

Remibrutinib in Sjogren's Syndrome Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/ZcKU7MgXlm https://t.co/P9JBlxcdcx

https://bit.ly/3Vsr4Zl

Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. https://t.co/pAeU3IzZfx https://t.co/rgJeHM5t62

https://bit.ly/3OU6tux

Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG

ACR22: Polymyalgia Rheumatica in the Spotlight One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run. https://t.co/4BpvYlKijY https://t.co/fTYYdmcE9X

https://bit.ly/3VDlAdY

Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/z3RTFt1hPb https://t.co/7rGn41qeu9

https://bit.ly/3OWPdoo

The Great Debate: To Treat or Not to Treat Pre RA Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22. https://t.co/s8FQ2l7k6Z https://t.co/zICWqhTfGL

https://bit.ly/3B59Glo

Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/s02Ue47m6o https://t.co/FZYI7E8D3f

https://bit.ly/3iCR5qs

https://bit.ly/3isA6qx

https://bit.ly/3UtKdIQ

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients. https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw

https://bit.ly/3XVPxYL

Topics

All News

Do you get our email newsletter?